158 related articles for article (PubMed ID: 2544323)
1. Intramuscular administration of iron during long-term chelation therapy with 2,3-dimercaptosuccinic acid in a man with severe lead poisoning.
Haust HL; Inwood M; Spence JD; Poon HC; Peter F
Clin Biochem; 1989 Jun; 22(3):189-96. PubMed ID: 2544323
[TBL] [Abstract][Full Text] [Related]
2. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning.
Bradberry S; Vale A
Clin Toxicol (Phila); 2009 Aug; 47(7):617-31. PubMed ID: 19663612
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy.
Cory-Slechta DA
J Pharmacol Exp Ther; 1988 Jul; 246(1):84-91. PubMed ID: 2839672
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication.
Flora SJ; Pande M; Mehta A
Chem Biol Interact; 2003 Jun; 145(3):267-80. PubMed ID: 12732454
[TBL] [Abstract][Full Text] [Related]
5. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication.
Graziano JH; Siris ES; LoIacono N; Silverberg SJ; Turgeon L
Clin Pharmacol Ther; 1985 Apr; 37(4):431-8. PubMed ID: 2983924
[TBL] [Abstract][Full Text] [Related]
6. Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men.
Torres-Alanís O; Garza-Ocañas L; Piñeyro-López A
Hum Exp Toxicol; 2002 Nov; 21(11):573-7. PubMed ID: 12507251
[TBL] [Abstract][Full Text] [Related]
7. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication.
Graziano JH; Lolacono NJ; Moulton T; Mitchell ME; Slavkovich V; Zarate C
J Pediatr; 1992 Jan; 120(1):133-9. PubMed ID: 1309865
[TBL] [Abstract][Full Text] [Related]
8. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning.
Bradberry S; Sheehan T; Vale A
QJM; 2009 Oct; 102(10):721-32. PubMed ID: 19700440
[TBL] [Abstract][Full Text] [Related]
9. Combined chelation therapy in reducing tissue lead concentrations in suckling rats.
Kostial K; Blanusa M; Piasek M; Restek-Samarzija N; Jones MM; Singh PK
J Appl Toxicol; 1999; 19(3):143-7. PubMed ID: 10362263
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model.
Smith D; Bayer L; Strupp BJ
Environ Res; 1998 Aug; 78(2):168-76. PubMed ID: 9719621
[TBL] [Abstract][Full Text] [Related]
11. Chelated lead in relation to lead in bone and ALAD genotype.
Gerhardsson L; Börjesson J; Mattsson S; Schütz A; Skerfving S
Environ Res; 1999 May; 80(4):389-98. PubMed ID: 10330313
[TBL] [Abstract][Full Text] [Related]
12. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning.
Bradberry S; Vale A
Clin Toxicol (Phila); 2009 Nov; 47(9):841-58. PubMed ID: 19852620
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures.
Chisolm JJ
Environ Health Perspect; 1990 Nov; 89():67-74. PubMed ID: 1965166
[TBL] [Abstract][Full Text] [Related]
14. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice.
Jones MM; Basinger MA; Gale GR; Atkins LM; Smith AB; Stone A
Toxicology; 1994 Apr; 89(2):91-100. PubMed ID: 8197593
[TBL] [Abstract][Full Text] [Related]
15. Modeling the effect of succimer (DMSA; dimercaptosuccinic acid) chelation therapy in patients poisoned by lead.
van Eijkeren JC; Olie JD; Bradberry SM; Vale JA; de Vries I; Clewell HJ; Meulenbelt J; Hunault CC
Clin Toxicol (Phila); 2017 Feb; 55(2):133-141. PubMed ID: 27919185
[TBL] [Abstract][Full Text] [Related]
16. Description of 3,180 courses of chelation with dimercaptosuccinic acid in children ≤ 5 y with severe lead poisoning in Zamfara, Northern Nigeria: a retrospective analysis of programme data.
Thurtle N; Greig J; Cooney L; Amitai Y; Ariti C; Brown MJ; Kosnett MJ; Moussally K; Sani-Gwarzo N; Akpan H; Shanks L; Dargan PI
PLoS Med; 2014 Oct; 11(10):e1001739. PubMed ID: 25291378
[TBL] [Abstract][Full Text] [Related]
17. Impacts of lead exposure and chelation therapy on bone metabolism during different developmental stages of rats.
Zhang Y; Zhou L; Li S; Liu J; Sun S; Ji X; Yan C; Xu J
Ecotoxicol Environ Saf; 2019 Nov; 183():109441. PubMed ID: 31404725
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure.
Cremin JD; Luck ML; Laughlin NK; Smith DR
Toxicol Appl Pharmacol; 1999 Dec; 161(3):283-93. PubMed ID: 10620486
[TBL] [Abstract][Full Text] [Related]
19. Disappearance of heme metabolites following chelation therapy with meso 2,3-dimercaptosuccinic acid (DMSA).
Tutunji MF; al-Mahasneh QM
J Toxicol Clin Toxicol; 1994; 32(3):267-76. PubMed ID: 8007034
[TBL] [Abstract][Full Text] [Related]
20. Succimer treatment during ongoing lead exposure reduces tissue lead in suckling rats.
Varnai VM; Piasek M; Blanusa M; Sarić MM; Kostial K
J Appl Toxicol; 2001; 21(5):415-6. PubMed ID: 11746184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
